Announced Sat, 30 May · 17:36 IST

1.Considered and approved Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended on March 31, 2026, and Auditors Report thereon;2. A declaration pursuant to ....

Revenue Growth 20pctPat NegativeEbitda Margin CompressionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.3%1-day move
₹15.15
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3-2.8+1.7-3.2-9.6-8.3-1.1-1.9
Up moveDown movePending
AI summary

Tejnaksh Healthcare Ltd reported audited standalone results for FY2026 with revenue of Rs 879.31 lakhs, up 22.5% from Rs 717.72 lakhs in FY2025. However, profit after tax declined significantly to Rs 137.98 lakhs from Rs 262.15 lakhs in the prior year. The consolidated PAT for Q4 was Rs 13.90 lakhs. The statutory auditor Maheshwari & Co issued an unmodified (clean) opinion on both standalone and consolidated financial results. The Board decided not to proceed with the proposed Rights Issue of shares, citing postponement of the company's expansion plans. The company reappointed Kapil Tulsani & Associates as internal auditor for FY2027. EBITDA margin compressed substantially from approximately 67% to 37%, indicating cost pressures despite revenue growth.

Likely market impact

The company shows revenue growth but with significant profit decline and margin compression, which may concern investors. The cancellation of the Rights Issue signals the company is scaling back expansion plans, potentially affecting future growth prospects. The clean audit opinion provides some comfort on financial reporting quality.